Nuvectis Pharma IncNVCT
Price$20.72

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$27.8MTTM through 30 Jun 2026
Free Cash Flow -$19.5MTTM through 30 Jun 2026

Margins

Current

Returns

-191.0%ROE
-106.9%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.27x
Net Debt-$25.1Mnet cash position
Cash & Equivalents$22.2M

Quality Metrics

Altman Z-Score23.06
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Diluted EPS-$1.32TTM
'21'22'23'24'25
FY2025: $-1.21

Dividend

No dividend

Capital Allocation

R&D Spend$19.7M

Segment Performance

SegmentRevenueYoYOutlook
Oncology Drug Development$0
View details

Preliminary Phase 1b data readout for NXP900 is expected in summer 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.